BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013;2:e23803. [PMID: 23734328 DOI: 10.4161/onci.23803] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014;3:e27048. [PMID: 24605265 DOI: 10.4161/onci.27048] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 59.0] [Reference Citation Analysis]
2 Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2013;2:e24850. [PMID: 24073369 DOI: 10.4161/onci.24850] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
3 Calvet CY, André FM, Mir LM. Dual therapeutic benefit of electroporation-mediated DNA vaccination in vivo: Enhanced gene transfer and adjuvant activity. Oncoimmunology 2014;3:e28540. [PMID: 25050220 DOI: 10.4161/onci.28540] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
4 Maby P, Bindea G, Mlecnik B, Galon J. License to kill: microsatellite instability and immune contexture. Oncoimmunology 2021;10:1905935. [PMID: 33868790 DOI: 10.1080/2162402X.2021.1905935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Parmiani G, Cimminiello C, Maccalli C. Increasing immunogenicity of cancer vaccines to improve their clinical outcome. Expert Rev Vaccines 2013;12:1111-3. [PMID: 24124873 DOI: 10.1586/14760584.2013.839274] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
6 Ali AA, Mccrudden CM, Mccaffrey J, Mcbride JW, Cole G, Dunne NJ, Robson T, Kissenpfennig A, Donnelly RF, Mccarthy HO. DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles. Nanomedicine: Nanotechnology, Biology and Medicine 2017;13:921-32. [DOI: 10.1016/j.nano.2016.11.019] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
7 Gibson HM, Veenstra JJ, Jones R, Vaishampayan U, Sauerbrey M, Bepler G, Lum L, Reyes J, Weise A, Wei WZ. Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination. Cancer Immunol Res 2015;3:777-86. [PMID: 25711535 DOI: 10.1158/2326-6066.CIR-14-0175] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
8 Dadar M, Chakraborty S, Dhama K, Prasad M, Khandia R, Hassan S, Munjal A, Tiwari R, Karthik K, Kumar D, Iqbal HMN, Chaicumpa W. Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus. Front Immunol 2018;9:2478. [PMID: 30483247 DOI: 10.3389/fimmu.2018.02478] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
9 Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology 2013;2:e26621. [PMID: 24498550 DOI: 10.4161/onci.26621] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 8.2] [Reference Citation Analysis]
10 Marć MA, Domínguez-Álvarez E, Gamazo C. Nucleic acid vaccination strategies against infectious diseases. Expert Opin Drug Deliv 2015;12:1851-65. [PMID: 26365499 DOI: 10.1517/17425247.2015.1077559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
11 Calvet CY, Thalmensi J, Liard C, Pliquet E, Bestetti T, Huet T, Langlade-Demoyen P, Mir LM. Optimization of a gene electrotransfer procedure for efficient intradermal immunization with an hTERT-based DNA vaccine in mice. Mol Ther Methods Clin Dev 2014;1:14045. [PMID: 26015983 DOI: 10.1038/mtm.2014.45] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
12 Kallerup RS, Foged C. Classification of Vaccines. In: Foged C, Rades T, Perrie Y, Hook S, editors. Subunit Vaccine Delivery. New York: Springer; 2015. pp. 15-29. [DOI: 10.1007/978-1-4939-1417-3_2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
13 Sedlik C, Vigneron J, Torrieri-Dramard L, Pitoiset F, Denizeau J, Chesneau C, de la Rochere P, Lantz O, Thery C, Bellier B. Different immunogenicity but similar antitumor efficacy of two DNA vaccines coding for an antigen secreted in different membrane vesicle-associated forms. J Extracell Vesicles 2014;3. [PMID: 25206960 DOI: 10.3402/jev.v3.24646] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
14 Hegmans JP, Aerts JG. Immunomodulation in cancer. Current Opinion in Pharmacology 2014;17:17-21. [DOI: 10.1016/j.coph.2014.06.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
15 Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2014;3:e28344. [PMID: 25050207 DOI: 10.4161/onci.28344] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
16 Yang Y, Shao Z, Gao J. Antitumor Effect of a DNA Vaccine Harboring Prostate Cancer-Specific Antigen with IL-12 as an Intramolecular Adjuvant. J Mol Microbiol Biotechnol 2017;27:168-74. [PMID: 28772273 DOI: 10.1159/000477245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015;4:e1008814. [PMID: 26137403 DOI: 10.1080/2162402X.2015.1008814] [Cited by in Crossref: 65] [Cited by in F6Publishing: 47] [Article Influence: 9.3] [Reference Citation Analysis]
18 Mitkin NA, Ustiugova AS, Uvarova AN, Rumyantsev KA, Korneev KV, Pavshintsev VV. Serum of Mice Immunized with MT1-MMP Metalloproteinase Reduces Migration Potential of Pancreatic Cancer Cells. Mol Biol 2021;55:910-8. [DOI: 10.1134/s0026893321050095] [Reference Citation Analysis]
19 Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology 2016;5:e1115942. [PMID: 27057468 DOI: 10.1080/2162402X.2015.1115942] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
20 Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2014;3:e957994. [PMID: 25941578 DOI: 10.4161/21624011.2014.957994] [Cited by in Crossref: 146] [Cited by in F6Publishing: 151] [Article Influence: 18.3] [Reference Citation Analysis]
21 Jensen BAH, Steffensen MA, Nielsen KN, Christensen JP, Thomsen AR, Holst PJ. Co-expression of tumor antigen and interleukin-2 from an adenoviral vector augments the efficiency of therapeutic tumor vaccination. Mol Ther 2014;22:2107-17. [PMID: 25023330 DOI: 10.1038/mt.2014.130] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
22 Liu J, Miao L, Sui J, Hao Y, Huang G. Nanoparticle cancer vaccines: Design considerations and recent advances. Asian J Pharm Sci 2020;15:576-90. [PMID: 33193861 DOI: 10.1016/j.ajps.2019.10.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
23 Gabai VL, Shifrin VI. Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy. Int Rev Immunol 2014;33:375-82. [PMID: 25277339 DOI: 10.3109/08830185.2014.954699] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
24 Gordy JT, Luo K, Zhang H, Biragyn A, Markham RB. Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model. J Immunother Cancer 2016;4:96. [PMID: 28018602 DOI: 10.1186/s40425-016-0189-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
25 Vacchelli E, Prada N, Kepp O, Galluzzi L. Current trends of anticancer immunochemotherapy. Oncoimmunology 2013;2:e25396. [PMID: 23894726 DOI: 10.4161/onci.25396] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
26 Tiptiri-kourpeti A, Spyridopoulou K, Pappa A, Chlichlia K. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy. Pharmacology & Therapeutics 2016;165:32-49. [DOI: 10.1016/j.pharmthera.2016.05.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
27 Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology. 2013;2:e25771. [PMID: 24286020 DOI: 10.4161/onci.25771] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 9.4] [Reference Citation Analysis]
28 Lambricht L, Vanvarenberg K, De Beuckelaer A, Van Hoecke L, Grooten J, Ucakar B, Lipnik P, Sanders NN, Lienenklaus S, Préat V, Vandermeulen G. Coadministration of a Plasmid Encoding HIV-1 Gag Enhances the Efficacy of Cancer DNA Vaccines. Mol Ther 2016;24:1686-96. [PMID: 27434590 DOI: 10.1038/mt.2016.122] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
29 Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2013;2:e24612. [PMID: 23894720 DOI: 10.4161/onci.24612] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 9.8] [Reference Citation Analysis]
30 Chodon T, Koya RC, Odunsi K. Active Immunotherapy of Cancer. Immunological Investigations 2015;44:817-36. [DOI: 10.3109/08820139.2015.1096684] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
31 Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology 2014;3:e28185. [PMID: 24800178 DOI: 10.4161/onci.28185] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
32 Pierini S, Perales-Linares R, Uribe-Herranz M, Pol JG, Zitvogel L, Kroemer G, Facciabene A, Galluzzi L. Trial watch: DNA-based vaccines for oncological indications. Oncoimmunology 2017;6:e1398878. [PMID: 29209575 DOI: 10.1080/2162402X.2017.1398878] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
33 Wen S, Zhang J, Zhou P, Luo C, Liu Y, Xu Z, Chen X, Ma H. The anti-tumour effect of a DNA vaccine carrying a fusion gene of human VEGFR2 and IL-12. Biotechnology & Biotechnological Equipment 2016;30:956-62. [DOI: 10.1080/13102818.2016.1207488] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Hickman ES, Lomax ME, Jakobsen BK. Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies. J Biomol Screen 2016;21:769-85. [PMID: 26993321 DOI: 10.1177/1087057116637837] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
35 Geary SM, Salem AK. Prostate cancer vaccines: Update on clinical development. Oncoimmunology 2013;2:e24523. [PMID: 23762812 DOI: 10.4161/onci.24523] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
36 Li L, Goedegebuure SP, Fleming TP, Gillanders WE. Developing a clinical development paradigm for translation of a mammaglobin-A DNA vaccine. Immunotherapy 2015;7:709-11. [PMID: 26250406 DOI: 10.2217/imt.15.40] [Reference Citation Analysis]
37 Tiriveedhi V, Tucker N, Herndon J, Li L, Sturmoski M, Ellis M, Ma C, Naughton M, Lockhart AC, Gao F, Fleming T, Goedegebuure P, Mohanakumar T, Gillanders WE. Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer. Clin Cancer Res 2014;20:5964-75. [PMID: 25451106 DOI: 10.1158/1078-0432.CCR-14-0059] [Cited by in Crossref: 46] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
38 Lambricht L, Lopes A, Kos S, Sersa G, Préat V, Vandermeulen G. Clinical potential of electroporation for gene therapy and DNA vaccine delivery. Expert Opin Drug Deliv 2016;13:295-310. [PMID: 26578324 DOI: 10.1517/17425247.2016.1121990] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 14.3] [Reference Citation Analysis]
39 Walther W, Schlag PM. Current status of gene therapy for cancer. Curr Opin Oncol 2013;25:659-64. [PMID: 24100345 DOI: 10.1097/CCO.0000000000000004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
40 Guan X, Chen J, Hu Y, Lin L, Sun P, Tian H, Chen X. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase. Biomaterials 2018;171:198-206. [PMID: 29698869 DOI: 10.1016/j.biomaterials.2018.04.039] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 13.5] [Reference Citation Analysis]
41 Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013;2:e24238. [PMID: 23762803 DOI: 10.4161/onci.24238] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
42 Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology 2015;4:e985940. [PMID: 25949870 DOI: 10.4161/2162402X.2014.985940] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
43 Fan Y, Moon JJ. Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines (Basel) 2015;3:662-85. [PMID: 26350600 DOI: 10.3390/vaccines3030662] [Cited by in Crossref: 151] [Cited by in F6Publishing: 137] [Article Influence: 21.6] [Reference Citation Analysis]
44 Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology 2013;2:e26494. [PMID: 24482747 DOI: 10.4161/onci.26494] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
45 Meleshko AN, Petrovskaya NA, Savelyeva N, Vashkevich KP, Doronina SN, Sachivko NV. Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma. Hum Vaccin Immunother 2017;13:1-6. [PMID: 28272989 DOI: 10.1080/21645515.2017.1285477] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
46 Khalili S, Rahbar MR, Dezfulian MH, Jahangiri A. In silico analyses of Wilms׳ tumor protein to designing a novel multi-epitope DNA vaccine against cancer. Journal of Theoretical Biology 2015;379:66-78. [DOI: 10.1016/j.jtbi.2015.04.026] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
47 Bobanga ID, Petrosiute A, Huang AY. Chemokines as Cancer Vaccine Adjuvants. Vaccines (Basel) 2013;1:444-62. [PMID: 24967094 DOI: 10.3390/vaccines1040444] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
48 Gabai V, Venanzi FM, Bagashova E, Rud O, Mariotti F, Vullo C, Catone G, Sherman MY, Concetti A, Chursov A. Pilot study of p62 DNA vaccine in dogs with mammary tumors. Oncotarget. 2014;5:12803-12810. [PMID: 25296974 DOI: 10.18632/oncotarget.2516] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
49 Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2014;3:e27878. [PMID: 24800173 DOI: 10.4161/onci.27878] [Cited by in Crossref: 99] [Cited by in F6Publishing: 102] [Article Influence: 12.4] [Reference Citation Analysis]
50 Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer 2020;20:662-80. [PMID: 32753728 DOI: 10.1038/s41568-020-0285-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 132] [Article Influence: 61.0] [Reference Citation Analysis]
51 Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013;2:e25595. [PMID: 24319634 DOI: 10.4161/onci.25595] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 7.7] [Reference Citation Analysis]
52 Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2013;2:e25238. [PMID: 24083080 DOI: 10.4161/onci.25238] [Cited by in Crossref: 106] [Cited by in F6Publishing: 107] [Article Influence: 11.8] [Reference Citation Analysis]
53 Pahle J, Walther W. Vectors and strategies for nonviral cancer gene therapy. Expert Opin Biol Ther 2016;16:443-61. [PMID: 26761200 DOI: 10.1517/14712598.2016.1134480] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 8.8] [Reference Citation Analysis]
54 Galluzzi L, Kroemer G, Eggermont A. Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology. 2014;3:e967147. [PMID: 25941597 DOI: 10.4161/21624011.2014.967147] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
55 Oates J, Hassan NJ, Jakobsen BK. ImmTACs for targeted cancer therapy: Why, what, how, and which. Molecular Immunology 2015;67:67-74. [DOI: 10.1016/j.molimm.2015.01.024] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 7.4] [Reference Citation Analysis]
56 Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology 2015;4:e1026531. [PMID: 26155408 DOI: 10.1080/2162402X.2015.1026531] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
57 Obeid J, Hu Y, Slingluff CL Jr. Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges. Semin Oncol 2015;42:549-61. [PMID: 26320060 DOI: 10.1053/j.seminoncol.2015.05.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
58 Rolih V, Barutello G, Iussich S, De Maria R, Quaglino E, Buracco P, Cavallo F, Riccardo F. CSPG4: a prototype oncoantigen for translational immunotherapy studies. J Transl Med 2017;15:151. [PMID: 28668095 DOI: 10.1186/s12967-017-1250-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]